ABEONA THERAPEUTICS INC. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
ABEONA THERAPEUTICS INC. (ABEO) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $29.00 thousand as of 2021-09-30, per its 10-Q filed 2021-11-15.
Discontinued › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2021-11-15
- 2021-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $29.00K.
- 2021-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $58.00K.
- 2021-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $87.00K.
- 2020-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $43.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2021-09-30 | $29.00K 10-Q · filed 2021-11-15 |
| 2021-06-30 | $58.00K 10-Q · filed 2021-07-28 |
| 2021-03-31 | $87.00K 10-Q · filed 2021-05-17 |
| 2020-09-30 | $43.00K 10-Q · filed 2020-11-09 |
| 2020-06-30 | $86.00K 10-Q · filed 2020-08-10 |
| 2020-03-31 | $130.00K 10-Q · filed 2020-05-06 |
| 2019-09-30 | $1.29M 10-Q · filed 2019-11-12 |
| 2017-09-30 | $87.00K 10-Q · filed 2017-11-14 |
| 2017-06-30 | $173.00K 10-Q · filed 2017-08-14 |
| 2017-03-31 | $610.00K 10-Q · filed 2017-05-15 |
| 2016-09-30 | $203.00K 10-Q · filed 2016-11-14 |
| 2016-06-30 | $290.00K 10-Q · filed 2016-08-15 |
| 2016-03-31 | $436.00K 10-Q · filed 2016-05-16 |
| 2015-09-30 | $145.00K 10-Q · filed 2015-11-16 |
| 2015-06-30 | $291.00K 10-Q · filed 2015-08-14 |
| 2015-03-31 | $349.00K 10-Q · filed 2015-05-14 |
| 2012-09-30 | $11.00K 10-Q · filed 2012-11-14 |
| 2012-06-30 | $22.00K 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |